Photo from academic.microsoft.com
Fremanezumab is a fully humanized IgG2Δa/κ monoclonal antibody specific for calcitonin gene‐related peptide developed and approved for the preventive treatment of migraine in adults. The population pharmacokinetics (PK) of fremanezumab… Click to show full abstract
Fremanezumab is a fully humanized IgG2Δa/κ monoclonal antibody specific for calcitonin gene‐related peptide developed and approved for the preventive treatment of migraine in adults. The population pharmacokinetics (PK) of fremanezumab were characterized in healthy subjects and patients with chronic migraine and episodic migraine, including the effects of intrinsic and extrinsic factors on PK variability.
Keywords:
population pharmacokinetic;
subjects patients;
pharmacokinetic modelling;
healthy subjects;
modelling simulation
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!